Showing 3871-3880 of 4956 results for "".
- SU2C Calls for Increased Diversity in Cancer Trialshttps://practicaldermatology.com/news/su2c-calls-for-increased-diversity-in-cancer-trials/2460265/Stand Up to Cancer (SU2C) announced a new diversity initiative that aims to make sure current advances in diagnosing and treating cancers don’t leave anyone out. The lack of diverse participation in cancer clinical trials may be due to socio-economic, cultural, trust and
- Alma Rolls Out Opus Plasmahttps://practicaldermatology.com/news/alma-rolls-out-opus-plasma/2460264/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- Crown Aesthetics Introduces Progen PRP Advantagehttps://practicaldermatology.com/news/crown-aesthetics-introduces-progen-prp-advantage/2460263/Crown Aesthetics, a division of Crown Laboratories, Inc., launched ProGen PRP Advantage, an easy-to-use, single-spin system that features 15ml and 30ml tubes, yielding 7-15ml of 2x concentration PRP. With the launch of
- Cynosure Taps Todd Tillemans As New CEOhttps://practicaldermatology.com/news/cynosure-taps-todd-tillemans-as-new-ceo-2/2460262/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- Final Data Support Efficacy of Revian Red System for Hair Growthhttps://practicaldermatology.com/news/final-data-support-efficacy-of-revian-red-system-for-hair-growth/2460260/Final data from a randomized, double-blind study of the Revian Red hair growth system demonstrated the ability of the system to successfully stop hair loss and subsequently grow new hair. Findings were presented at the 2020 Winter Clinical Dermatology Conference – Hawaii and are <
- FDA Follow-Up Study: Sunscreen Active Ingredients Are Absorbed by Bloodstreamhttps://practicaldermatology.com/news/fda-follow-up-study-sunscreen-active-ingredients-are-absorbed-by-bloodstream/2460258/Six active ingredients administered in four different sunscreen formulations are systemically absorbed, according to a new report. The study was sponsored by U.S. Food and Drug Administration (FDA) and is a follow-up to a May 2019 study that generated a lot of headlines. The new report
- Move Over CoolSculpting? Fat-freezing Ice Slurries May Be the Next Big Thing in Body Contouringhttps://practicaldermatology.com/news/fat-freezing-ice-slurries-may-be-the-next-big-thing-in-body-contouring/2460255/An injectable ice “slurry” may selectively reduce unwanted fat, according to research in pigs published in Plastic & Reconstructive Surgery.
- South Beach Symposium Poised for 18th Miami Conferencehttps://practicaldermatology.com/news/south-beach-symposium-poised-for-18th-miami-conference/2460253/The 18th Annual South Beach Symposium takes place in Miami Beach next month. Organizers say the annual conference boasts an extensive agenda, with in-depth pre-conference offerings, and sessions topics covering the latest and most well-supported knowledge in clinical and aesthetic dermatology. Ro
- Patients Report 95 Percent Satisfaction Rate with Mohs Surgery for Melanomahttps://practicaldermatology.com/news/patients-report-95-percent-satisfaction-rate-with-mohs-surgery-for-melanoma-2/2460252/Patients who received Mohs surgery to treat melanoma reported a 95 percent long-term satisfaction rate with their results, according to a new study by UT Southwestern Medical Center dermatologists. The study, published in Dermatologic Surgery, is the first to poll pat
- Revance Acquires Exclusive US Distribution Rights to Teoxane SA Fillershttps://practicaldermatology.com/news/revance-acquires-exclusive-us-distribution-rights-to-teoxane-sa-fillers-1/2460250/Revance Therapeutics, Inc. is the exclusive commercialization partner of Teoxane SA in the US. With a new distribution agreement just announced, Revance gains immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (RHA®) line of fillers in the